BLIS TechnologiesNZSE:BLT Operating Margin % is -13.86% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, BLIS Technologies ranks better than 67.27% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
BLIS Technologies Operating Margin % Related Terms
BLIS Technologies Operating Margin % Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, BLIS Technologies's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Operating Margin % distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BLIS Technologies's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a Operating Margin % of -13.86% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on BLIS Technologies and its competitors. According to the industry distribution chart, BLIS Technologies ranks #309 out of 944 companies in the Biotechnology industry, placing it in the top 32.7%.
Is BLIS Technologies' Operating Margin % too high?
BLIS Technologies' current Operating Margin % is -13.86%. Based on the distribution chart, BLIS Technologies ranks #309 out of 944 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #309 out of 944 companies for Operating Margin %. This puts BLIS Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on BLIS Technologies and its competitors. BLIS Technologies's current Operating Margin % is -13.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current Operating Margin % is -13.86%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Operating Margin % is -13.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 